Literature DB >> 8752146

Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival.

K S Iwamoto1, T Mizuno, T Ito, N Tsuyama, S Kyoizumi, T Seyama.   

Abstract

Missense mutations are by the far the most common types of mutations found in p53 of human tumors, suggesting that mutant p53 proteins function either by abrogating wild-type function or by gaining new oncogenic functions. To distinguish between the dominant-negative effect and gain of new function of p53 missense mutants, we measured the ability of transfected missense mutant p53s in p53-null Jurkat cells to alter T-cell receptor (TCR) surface expression. The TCR is a key signal transduction moiety common to T lymphocytes and is one of the major sites for aberrations in T-cell leukemias/lymphomas. Three p53 mutants (248trp, 249ser, and 273his) enhanced the frequency of TCR mutants after graded doses of X-radiation compared to null p53 parent- and wild-type p53-possessing normal lymphocytes; the parent Jurkat and normal lymphocyte showed no difference. These enhancements were not the results of a change in radiosensitivity or in G1 checkpoint arrest characteristics. Therefore, the creation of this mutator phenotype by missense-type p53 mutations implies that a more direct mechanism, apart from changes of cell cycle kinetics or cell death, may be responsible for the selection of certain p53 point mutations, which eventually result in the tumorigenesis of the cell.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8752146

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

Review 2.  Links between mutant p53 and genomic instability.

Authors:  Walter Hanel; Ute M Moll
Journal:  J Cell Biochem       Date:  2012-02       Impact factor: 4.429

3.  Activation of Bak in ultrasound-induced, JNK- and p38-independent apoptosis and its inhibition by Bcl-2.

Authors:  Manabu Kinoshita; Yutaka Eguchi; Kullervo Hynynen
Journal:  Biochem Biophys Res Commun       Date:  2006-12-18       Impact factor: 3.575

4.  Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53.

Authors:  Yoichi Ohiro; Anny Usheva; Shinichiro Kobayashi; Shannon L Duffy; Regan Nantz; David Gius; Nobuo Horikoshi
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

5.  Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor.

Authors:  Rami Aqeilan; Rotem Kedar; Ahmi Ben-Yehudah; Haya Lorberboum-Galski
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

6.  An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control.

Authors:  A Gualberto; K Aldape; K Kozakiewicz; T D Tlsty
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

7.  A mutated p53 status did not prevent the induction of apoptosis by sulforaphane, a promising anti-cancer drug.

Authors:  Carmela Fimognari; Luca Sangiorgi; Silvia Capponcelli; Michael Nüsse; Silvia Fontanesi; Fausto Berti; Silvia Soddu; Giorgio Cantelli-Forti; Patrizia Hrelia
Journal:  Invest New Drugs       Date:  2005-06       Impact factor: 3.850

8.  Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling.

Authors:  Kwan-Young Jung; Ramin Samadani; Jay Chauhan; Kerrick Nevels; Jeremy L Yap; Jun Zhang; Shilpa Worlikar; Maryanna E Lanning; Lijia Chen; Mary Ensey; Sagar Shukla; Rosene Salmo; Geoffrey Heinzl; Caryn Gordon; Troy Dukes; Alexander D MacKerell; Paul Shapiro; Steven Fletcher
Journal:  Org Biomol Chem       Date:  2013-06-14       Impact factor: 3.876

Review 9.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

10.  Ectopic expression of cdc2/cdc28 kinase subunit Homo sapiens 1 uncouples cyclin B metabolism from the mitotic spindle cell cycle checkpoint.

Authors:  M L Hixon; A I Flores; M W Wagner; A Gualberto
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.